US7737142 — (Thio) carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
Method of Use · Assigned to Richter Gedeon Vegyeszeti Gyar RT · Expires 2029-09-17 · 3y remaining
What this patent protects
This patent protects new compounds that act as D3 and D2 dopamine receptor antagonists and their production processes, as well as pharmaceutical compositions containing them.
USPTO Abstract
The present invention relates to new D3 and D2 dopamine receptor subtype preferring ligands of formula (I): wherein R 1 and R 2 represent independently a substituent selected from hydrogen, alkyl, aryl, cycloalkyl, aroyl, or R 1 and R 2 may form a heterocyclic ring with the adjacent nitrogen atom; X represents an oxygen or sulphur atom; n is an integer of from 1 to 2, and/or geometric isomers and/or stereoisomers and/or diastereomers and/or salts and/or hydrates and/or solvates thereof, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of a condition which requires modulation of dopamine receptors.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2543 |
— | cariprazine-hydrochloride |
U-2543 |
— | cariprazine-hydrochloride |
U-2544 |
— | cariprazine-hydrochloride |
U-2545 |
— | cariprazine-hydrochloride |
U-1750 |
— | cariprazine-hydrochloride |
U-2543 |
— | cariprazine-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.